Menarini Group: Breast Neoplasms trials

The registry lists 12 Breast Neoplasms studies with Menarini Group as lead sponsor. 4 are open to participants now and 2 have results posted.

Phase 1 6Phase 2 4Phase 3 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast CancerRecruitingNCT07766018Phase 2
• A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer PatientsRecruitingNCT06833853
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceRecruitingNCT06492616Phase 3
• Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingNCT05386108Phase 1/2
• Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerCompletedNCT03778931Phase 3Results posted
• MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast CancerCompletedNCT03767335Phase 1Results posted
• ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)Active, not recruitingNCT05662345
• ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyActive, not recruitingNCT05596409Phase 2
• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingNCT05563220Phase 1/2
• Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast CancerCompletedNCT03088527Phase 1
• Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast CancerCompletedNCT02650817Phase 1
• A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast CancerCompletedNCT02338349Phase 1